Drug slows cognitive decline in Alzheimer’s patients, study reveals
by Ian Sample Science editor from on (#66AX7)
Antibody therapy lecanemab removes clumps of protein called beta amyloid that builds up in brain
Researchers have hailed the dawn of a new era of Alzheimer's therapies after a clinical trial confirmed that a drug slows cognitive decline in patients with early stages of the disease.
The result comes after decades of failure in the field and encouraged experts to say Alzheimer's - which affects 30 million people worldwide - could be treatable.
Continue reading...